R&D Trends

Cloud Pharmaceuticals, University of Florida collaborate

Wednesday, March 18, 2015 01:09 PM

Cloud Pharmaceuticals, a Research Triangle Park, N.C.-based therapeutics company focused on cloud-based drug design and development, and the University of Florida’s department of medicine have announced an academic collaboration to help rapidly design and develop novel drugs to inhibit the reproduction of cancer cells.

More... »


Study: How much should cancer drugs cost?

Monday, March 16, 2015 01:54 PM

The true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered, according to a Cornell University researchers based on a study, A Quality-Adjusted Price Index for Colorectal Cancer Drugs, released by the National Bureau of Economic Research (NBER).

More... »


New immunotechnology center MI-mAbs launched

Monday, March 16, 2015 01:48 PM

MI-mAbs, a new immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease and founding member of the France-based Marseille Immunopole (MI) cluster, has announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Universite (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC); three of their research centers (the Centre d'Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Center for Immunophenomics); Innate Pharma, a European immuno-oncology company; and Sanofi.

More... »

Second Genome, Evotec to collaborate in microbiome discovery and development

Monday, March 16, 2015 01:47 PM

Evotec, a drug discovery alliance and development partnership company based in Germany, and Second Genome, a South San Francisco-based therapeutic developer, are collaborating on small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

More... »

Report: Declining Ebola cases pose serious challenge to clinical studies

Thursday, March 12, 2015 01:01 PM

The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the disease, as it will be more difficult to recruit study participants and demonstrate efficacy, said an analyst with research and consulting firm GlobalData.

More... »

Report: U.S. prescription drug spending increased 13.1% in 2014

Thursday, March 12, 2015 12:56 PM

New hepatitis C therapies with high price tags and the exploitation of loopholes for compounded medications drove a 13.1% increase in U.S. drug spending in 2014—a rate not seen in more than a decade—according to new data released in the 2014 Express Scripts Drug Trend Report. Headquartered in St. Louis, Mo., Express Scripts provides integrated pharmacy-benefit management services.

More... »

AstraZeneca to collaborate with Singapore research organizations on heart failure

Wednesday, March 11, 2015 12:26 PM

AstraZeneca has formed a two-year collaboration with Singapore organizations including the Agency for Science, Technology and Research (A*STAR), National University Heart Center, Singapore (NUHCS) and National University of Singapore to support research into new therapies for heart failure.

More... »

Illumina, Merck Serono collaborate to expand companion diagnostics for oncology

Wednesday, March 11, 2015 12:22 PM

Illumina, a San Diego-based provider of sequencing and array-based technologies, has formed a collaboration with Merck Serono, the biopharmaceuticals business of Merck, based in Darmstadt, Germany, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic.

More... »

MedImmune, Joslin Diabetes Center collaborate on metabolic disease research

Wednesday, March 11, 2015 12:21 PM

MedImmune, the global biologics R&D arm of AstraZeneca, and Joslin Diabetes Center, a diabetes research and clinical care organization based in Boston, Mass., have inked a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity and related metabolic disorders.

More... »

Epic Sciences, Prostate Cancer Clinical Trials Consortium collaborate

Monday, March 9, 2015 12:22 PM

Epic Sciences, a San Diego, Calif.-based developer of novel diagnostics to personalize and advance the treatment and management of cancer, and the Prostate Cancer Clinical Trials Consortium (PCCTC), a consortium for phase I/II and phase II clinical trials in prostate cancer, will collaborate to apply Epic's circulating tumor cell (CTC) technology in multiple investigator-initiated clinical trials to advance the development of new prostate cancer treatments.

More... »

CenterWatch
CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs